Sociedad Argentina de Hematología












ISSN 2250-8309


Formulario de cesión
de Derechos de Autor

Se solicita enviar el siguiente formulario, debidamente firmado por todos los autores del trabajo presentado

por Fax (11) 48552452

o personalmente en la SAH
o en archivo PDF por mail

Formulario de Cesión de Derechos de Autor



  REVISTA ARGENTINA DE HEMATOLOGÍA                                                                                    « Back »

Volumen:    21    # Number : 2

Publication Date :    MAYO - AGOSTO    Year:    2017


First generation FLT3 inhibitors sorafenib and midostaurin in acute myeloid leukemia
Authors: Fernández I I

Abstract: FLT3 is one of the most commonly mutated genes in AML, in about 30% of patients (pts). The most frequent mutation that confers poor prognosis is tandem duplication within the juxtamembrane domain of that receptor (FLT3-ITD). Less frequently, point mutations of the tyrosine kinase (TK) domain are detected. Sorafenib and midostaurin are inhibitors of multikinases, not specific for FLT3 mutations and have been evaluated as monotherapy with transient responses in relapsed or refractory (r/r), possibly due to lack of potency and specificity. The results of recent clinical trials show the potential benefit of the ITKs in pts with newly diagnosed AML in combination with standard chemotherapy for induction, consolidation, maintenance and posttransplantation.

Key words: FLT3 inhibitors, Sorafenib, Midostaurin, Acute myeloid leukemia.

Pages :

  Resumen             pdf  

Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485